<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Curis, Inc. — News on 6ix</title>
<link>https://6ix.com/company/curis-inc</link>
<description>Latest news and press releases for Curis, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 19 Mar 2026 20:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/curis-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835595878dffbe2df0eaffa.webp</url>
<title>Curis, Inc.</title>
<link>https://6ix.com/company/curis-inc</link>
</image>
<item>
<title>Curis Provides Fourth Quarter 2025 Business Update</title>
<link>https://6ix.com/company/curis-inc/news/curis-provides-fourth-quarter-2025-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/curis-inc/news/curis-provides-fourth-quarter-2025-business-update</guid>
<pubDate>Thu, 19 Mar 2026 20:00:00 GMT</pubDate>
<description>Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business update and financial results for the quarter ended December 31, 2025.</description>
</item>
<item>
<title>Curis to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on March 19, 2026</title>
<link>https://6ix.com/company/curis-inc/news/curis-to-report-fourth-quarter-2025-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-19-2026</link>
<guid isPermaLink="true">https://6ix.com/company/curis-inc/news/curis-to-report-fourth-quarter-2025-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-19-2026</guid>
<pubDate>Thu, 12 Mar 2026 20:27:00 GMT</pubDate>
<description>Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its fourth quarter 2025 financial and operating results on Thursday, March 19, 2026, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET.</description>
</item>
<item>
<title>Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds</title>
<link>https://6ix.com/company/curis-inc/news/curis-announces-closing-private-placement-130000242</link>
<guid isPermaLink="true">https://6ix.com/company/curis-inc/news/curis-announces-closing-private-placement-130000242</guid>
<pubDate>Fri, 09 Jan 2026 13:00:00 GMT</pubDate>
<description>Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the closing of its previously announced private placement (the "PIPE financing") for gross proceeds of up to $80.8 million to the Company, including initial gross proceeds to the Company of approximately $20.2 million, in each case before placement agent fees and offering expenses.</description>
</item>
<item>
<title>Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds</title>
<link>https://6ix.com/company/curis-inc/news/curis-announces-pricing-private-placement-134500045</link>
<guid isPermaLink="true">https://6ix.com/company/curis-inc/news/curis-announces-pricing-private-placement-134500045</guid>
<pubDate>Wed, 07 Jan 2026 13:45:00 GMT</pubDate>
<description>Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it has entered into a securities purchase agreement with new and existing healthcare-focused, high-quality institutional investors and certain insiders of the Company for a private placement (the "PIPE financing") for gross proceeds of up to $80.8 million to the Company, including initial gross proceeds to the</description>
</item>
<item>
<title>Curis Provides Updated Data from its Frontline AML Triplet Study</title>
<link>https://6ix.com/company/curis-inc/news/curis-provides-updated-data-frontline-130000205</link>
<guid isPermaLink="true">https://6ix.com/company/curis-inc/news/curis-provides-updated-data-frontline-130000205</guid>
<pubDate>Tue, 09 Dec 2025 13:00:00 GMT</pubDate>
<description>Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, yesterday provided updated clinical data from the ongoing frontline Acute Myeloid Leukemia (AML) triplet study (CA-4948-104) in a poster presentation at the 67th ASH Annual Meeting (ASH).</description>
</item>
<item>
<title>Curis to Present at Upcoming 30th Annual SNO Meeting</title>
<link>https://6ix.com/company/curis-inc/news/curis-present-upcoming-30th-annual-142600319</link>
<guid isPermaLink="true">https://6ix.com/company/curis-inc/news/curis-present-upcoming-30th-annual-142600319</guid>
<pubDate>Fri, 14 Nov 2025 14:26:00 GMT</pubDate>
<description>Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that Curis will report emavusertib and BTKi clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) in three presentations and preclinical data on emavusertib in an oral presentation at the 30th Annual Meeting of the Society for Neuro-Oncology (SNO) on November 19-23:</description>
</item>
<item>
<title>Curis Provides Third Quarter 2025 Business Update</title>
<link>https://6ix.com/company/curis-inc/news/curis-provides-third-quarter-2025-210000941</link>
<guid isPermaLink="true">https://6ix.com/company/curis-inc/news/curis-provides-third-quarter-2025-210000941</guid>
<pubDate>Thu, 06 Nov 2025 21:00:00 GMT</pubDate>
<description>Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its financial and operating results for the third quarter ended September 30, 2025.</description>
</item>
<item>
<title>Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025</title>
<link>https://6ix.com/company/curis-inc/news/curis-report-third-quarter-2025-200000433</link>
<guid isPermaLink="true">https://6ix.com/company/curis-inc/news/curis-report-third-quarter-2025-200000433</guid>
<pubDate>Thu, 30 Oct 2025 20:00:00 GMT</pubDate>
<description>Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast on the same day at 4:30 p.m. ET.</description>
</item>
<item>
<title>Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/curis-inc/news/curis-reports-inducement-grants-under-200000005</link>
<guid isPermaLink="true">https://6ix.com/company/curis-inc/news/curis-reports-inducement-grants-under-200000005</guid>
<pubDate>Fri, 03 Oct 2025 20:00:00 GMT</pubDate>
<description>Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that on October 1, 2025, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 84,750 shares of Curis common stock to two new employees, with a grant date of October 1, 2025 (the "Q4 2025 Inducement Grants").</description>
</item>
<item>
<title>Curis to Present at Upcoming Healthcare Conferences in September</title>
<link>https://6ix.com/company/curis-inc/news/curis-present-upcoming-healthcare-conferences-144200731</link>
<guid isPermaLink="true">https://6ix.com/company/curis-inc/news/curis-present-upcoming-healthcare-conferences-144200731</guid>
<pubDate>Tue, 02 Sep 2025 14:42:00 GMT</pubDate>
<description>Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences:</description>
</item>
<item>
<title>Curis Provides Second Quarter 2025 Business Update</title>
<link>https://6ix.com/company/curis-inc/news/curis-provides-second-quarter-2025-120000250</link>
<guid isPermaLink="true">https://6ix.com/company/curis-inc/news/curis-provides-second-quarter-2025-120000250</guid>
<pubDate>Tue, 05 Aug 2025 12:00:00 GMT</pubDate>
<description>Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its financial and operating results for the second quarter ended June 30, 2025.</description>
</item>
<item>
<title>Curis to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2025</title>
<link>https://6ix.com/company/curis-inc/news/curis-report-second-quarter-2025-123000253</link>
<guid isPermaLink="true">https://6ix.com/company/curis-inc/news/curis-report-second-quarter-2025-123000253</guid>
<pubDate>Tue, 29 Jul 2025 12:30:00 GMT</pubDate>
<description>Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its second quarter 2025 financial and operating results on Tuesday, August 5, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET.</description>
</item>
<item>
<title>Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement</title>
<link>https://6ix.com/company/curis-inc/news/curis-announces-7-0-million-123200407</link>
<guid isPermaLink="true">https://6ix.com/company/curis-inc/news/curis-announces-7-0-million-123200407</guid>
<pubDate>Wed, 02 Jul 2025 12:32:00 GMT</pubDate>
<description>Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive agreement with a combination of existing and new investors for the purchase of 1,538,460 shares ("Shares") of its common stock in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Curis also agreed to issue to the investors</description>
</item>
<item>
<title>Curis Provides First Quarter 2025 Business Update</title>
<link>https://6ix.com/company/curis-inc/news/curis-provides-first-quarter-2025-120000110</link>
<guid isPermaLink="true">https://6ix.com/company/curis-inc/news/curis-provides-first-quarter-2025-120000110</guid>
<pubDate>Tue, 06 May 2025 12:00:00 GMT</pubDate>
<description>Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the first quarter ended March 31, 2025.</description>
</item>
<item>
<title>Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025</title>
<link>https://6ix.com/company/curis-inc/news/curis-report-first-quarter-2025-120000022</link>
<guid isPermaLink="true">https://6ix.com/company/curis-inc/news/curis-report-first-quarter-2025-120000022</guid>
<pubDate>Tue, 29 Apr 2025 12:00:00 GMT</pubDate>
<description>Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET.</description>
</item>
<item>
<title>Curis to Present at Upcoming Healthcare Conference in April</title>
<link>https://6ix.com/company/curis-inc/news/curis-present-upcoming-healthcare-conference-200500231</link>
<guid isPermaLink="true">https://6ix.com/company/curis-inc/news/curis-present-upcoming-healthcare-conference-200500231</guid>
<pubDate>Wed, 02 Apr 2025 20:05:00 GMT</pubDate>
<description>Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in the Jones Healthcare and Technology Innovation Conference on Wednesday, April 9, 2025 with a fireside chat and company presentation.</description>
</item>
<item>
<title>Curis Provides Fourth Quarter 2024 Business Update</title>
<link>https://6ix.com/company/curis-inc/news/curis-provides-fourth-quarter-2024-120000997</link>
<guid isPermaLink="true">https://6ix.com/company/curis-inc/news/curis-provides-fourth-quarter-2024-120000997</guid>
<pubDate>Mon, 31 Mar 2025 12:00:00 GMT</pubDate>
<description>Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the quarter ended December 31, 2024.</description>
</item>
<item>
<title>Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025</title>
<link>https://6ix.com/company/curis-inc/news/curis-report-fourth-quarter-2024-200700425</link>
<guid isPermaLink="true">https://6ix.com/company/curis-inc/news/curis-report-fourth-quarter-2024-200700425</guid>
<pubDate>Fri, 28 Mar 2025 20:07:00 GMT</pubDate>
<description>Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial and operating results on Monday, March 31, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET.</description>
</item>
<item>
<title>Curis Provides Third Quarter 2024 Business Update</title>
<link>https://6ix.com/company/curis-inc/news/curis-provides-third-quarter-2024-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/curis-inc/news/curis-provides-third-quarter-2024-business-update</guid>
<pubDate>Thu, 14 Nov 2024 05:00:00 GMT</pubDate>
<description>Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., Nov. 14, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology</description>
</item>
<item>
<title>Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement</title>
<link>https://6ix.com/company/curis-inc/news/curis-announces-dollar121-million-registered-direct-and-concurrent-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/curis-inc/news/curis-announces-dollar121-million-registered-direct-and-concurrent-private-placement</guid>
<pubDate>Tue, 29 Oct 2024 04:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., Oct. 29, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib</description>
</item>
</channel>
</rss>